These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 11466912)
21. Prostate-specific antigen assay using whole blood samples spotted on filter paper and its application to mass screening for prostate cancer. Nanri M; Nanri K; Fujiyama C; Tokuda Y; Nakamura K; Uozumi J Int J Urol; 2007 Jun; 14(6):505-9. PubMed ID: 17593094 [TBL] [Abstract][Full Text] [Related]
22. Screening for prostate cancer: recommendations and rationale. Berg AO; Am J Nurs; 2003 Mar; 103(3):107-10; discussion 111. PubMed ID: 12626949 [No Abstract] [Full Text] [Related]
23. Can we accurately identify men with low risk prostate cancer? Neal DE J Urol; 2008 Oct; 180(4):1217-8. PubMed ID: 18707718 [No Abstract] [Full Text] [Related]
24. Non-systematic screening for prostate cancer in Sweden--survey from the National Prostate Cancer Registry. Stattin P; Johansson R; Damber JE; Hellström M; Hugosson J; Lundgren R; Varenhorst E; Johansson JE Scand J Urol Nephrol; 2003; 37(6):461-5. PubMed ID: 14675917 [TBL] [Abstract][Full Text] [Related]
25. Patient education. PSA: pros and cons. Gattellari M; Ward JE Aust Fam Physician; 2003 Jun; 32(6):429-30. PubMed ID: 12833769 [No Abstract] [Full Text] [Related]
27. Diagnosis and treatment of prostate cancer. Beyond the controversy over whether and whom to screen, the appropriate method of screening is also subject to debate. Loeb S; Catalona WJ Med Econ; 2008 Dec; 85(24):36-41. PubMed ID: 19209648 [No Abstract] [Full Text] [Related]
28. How important are the prostate-specific antigen assays? Vessella RL Contemp Intern Med; 1994 Feb; 6(2):76-89. PubMed ID: 10146682 [No Abstract] [Full Text] [Related]
29. Prostate cancer screening strategies with re-screening interval determined by individual baseline prostate-specific antigen values are cost-effective. Kobayashi T; Goto R; Ito K; Mitsumori K Eur J Surg Oncol; 2007 Aug; 33(6):783-9. PubMed ID: 17408910 [TBL] [Abstract][Full Text] [Related]
30. [The prostate specific antigen: what can we learn from the American experience?]. Zhao XJ Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(47):3313-5. PubMed ID: 16409833 [No Abstract] [Full Text] [Related]
31. Prostate cancer: current evidence weighs against population screening. Boyle P; Brawley OW CA Cancer J Clin; 2009; 59(4):220-4. PubMed ID: 19564244 [No Abstract] [Full Text] [Related]
32. Is the era of prostate-specific antigen over? Djavan B; Rocco B; Stangelberger A; De Cobelli O; Marberger M BJU Int; 2007 Jul; 100 Suppl 2():8-10. PubMed ID: 17594349 [No Abstract] [Full Text] [Related]
33. Prostate-specific antigen in screening for prostate cancer. Mayer FJ; Crawford ED West J Med; 1994 Feb; 160(2):168. PubMed ID: 7512780 [No Abstract] [Full Text] [Related]
34. Screening for prostate cancer. Detecting and extirpating premetastatic tumours seems a legitimate objective. Evans DJ BMJ; 1998 Jun; 316(7148):1903. PubMed ID: 9669856 [No Abstract] [Full Text] [Related]
35. Re: Is a screening interval of every 4 years for prostate cancer acceptable? Roobol MJ; Schröder FH J Natl Cancer Inst; 2008 Feb; 100(3):222; author reply 223-4. PubMed ID: 18230797 [No Abstract] [Full Text] [Related]
36. Prostate cancer and prostate-specific antigen (PSA) screening in Austria. Vutuc C; Schernhammer ES; Haidinger G; Waldhör T Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872 [TBL] [Abstract][Full Text] [Related]
37. The Japanese guideline for prostate cancer screening. Hamashima C; Nakayama T; Sagawa M; Saito H; Sobue T Jpn J Clin Oncol; 2009 Jun; 39(6):339-51. PubMed ID: 19346535 [TBL] [Abstract][Full Text] [Related]
38. [Screening of the prostate cancer. "lnstantaneous" of a daily practice among 300 general practitioners of the canton of Vaud]. Praz V; Jichlinski P; Aymon D; Leisinger HJ Rev Med Suisse; 2005 Dec; 1(44):2840-2. PubMed ID: 16382715 [TBL] [Abstract][Full Text] [Related]